ACRS241220C6000
- 0.54
- +0.09+20.00%
Aclaris Therapeutics Newsroom
Aclaris Therapeutics Raised to Outperform From Market Perform by Leerink Partners
A Quick Look at Today's Ratings for Aclaris Therapeutics(ACRS.US), With a Forecast Between $3 to $13
BTIG Upgrades Aclaris Therapeutics to Buy, Announces $8 Price Target
Aclaris Therapeutics Analyst Ratings
Aclaris Therapeutics: Hold Rating Amid Mixed Trial Outcomes and Strategic Uncertainties
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), McKesson (MCK) and Enhabit, Inc (EHAB)
Stifel Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating, Raises Target Price to $3
Stifel Nicolaus Sticks to Its Hold Rating for Aclaris Therapeutics (ACRS)
BTIG Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating
Aclaris Therapeutics Analyst Ratings
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating
Aclaris Therapeutics: Hold Rating Amidst Clinical Uncertainty and Strategic Review
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), Celcuity (CELC) and Intuitive Surgical (ISRG)
Aclaris Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS) and Immunocore Holdings (IMCR)
Aclaris Therapeutics: Cautious Hold Rating Amid Financial Stability and Pipeline Potential
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB), Aethlon Medical (AEMD) and Aclaris Therapeutics (ACRS)
Aclaris Therapeutics: Hold Rating Amidst Strategic Review and Clinical Setbacks
Aclaris Therapeutics Analyst Ratings